Full Text
HTA359 What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to Go Through the JCA?

Abstract

Authors

Charlie Hewitt Devan Hopkinson Sam Bean

Back to Volume 28, Supplemental Issue 12S1
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×